Study S001582

Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03151005
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 70
Start: 2017-07-01
Primary completion: 2021-04-01
Lead sponsor: Xinqiao Hospital of Chongqing
Conditions: Polycystic Ovary Syndrome (PCOS); Overweight; Obesity
Interventions: DRUG:Metformin-GLP-1 Receptor Agonist; DRUG:Metformin-Oral Contraceptive(OC)
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Assessment of Reproductive Functions [12 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007146	Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Liao M, Endocrine	2024	Randomized trial	PMID 37653215 DOI	cites ClinicalTrials.gov:NCT03151005; registry reference DERIVED:37653215
R0023564	GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. Jiang Y, Frontiers in pharmacology	2018	Preclinical	PMID 30459598 DOI	registry reference RESULT:30459598
R0024316	Insulin and the polycystic ovary syndrome. Macut D, Diabetes research and clinical practice	2017	Randomized trial	PMID 28646699 DOI	registry reference RESULT:28646699